The director of Laryngology Research at Mass Eye and Ear spoke to the use of machine learning programs to aid physicians in the diagnosis of dystonia.
Ericka Wong, MD, comments on gaps in care in myasthenia gravis and provides take-home messages for physicians treating patients with this condition.
The director of research for internal medicine and geriatrics at Indiana University School of Medicine discussed the advantages digital assessments bring to clinics, and what role they will play in the coming years. [WATCH TIME: 3 minutes]
The neuropathologist at Mount Sinai and chief science officer of Precise Dx pairing spoke to the role of artificial intelligence in the diagnosis of diseases from peripheral tissue biopsies and its ability to improve neuropathology. [WATCH TIME: 8 minutes]
A trio of clinicians from Georgetown University explore the current status of disease-modifying therapies for individuals with Parkinson disease.
The medical director of the Ohio State Sleep Medicine Institute provided insight on areas within sleep disorder care that need improvement, including the diagnostic process.
EEG Talk is a series dedicated to teaching electroencephalogram (EEG) reading skills in neurology in a way that is both digestible and fun. New episodes featuring special guests in the field are posted regularly on Mondays.
Jason Freeman, MD, MBA, and Hunter Davis, PharmD, discuss the poster “Patient Reported Outcomes and Clinical Disability Outcomes in MS demonstrate the same rates of worsening when performed in neurology clinic, patient registry, and a clinical trial” presented at AAN 2023. Sponsored By Novartis.
The clinical program manager at the Jefferson Center for Neurorestoration provided commentary on the state of neurorestoration and constant transformation of the space. [WATCH TIME: 3 minutes]
In recognition of World MS Day, the health and rehabilitation psychologist at the Rowan Center for Behavioral Medicine discussed types of interventions for managing cognitive changes in patients with multiple sclerosis. [WATCH TIME: 5 minutes]
As the field of MS care turns its sights on addressing progressive disease, the need for more biomarkers of disease activity and therapeutic target engagement is perhaps greater than ever.
The chair of neurology and Olemberg Family Chair of Neurological Disorders at the University of Miami Miller School of Medicine detailed the reasons behind the lack of research on social determinants of health on stroke outcomes.
Ahmed Obeidat, MD, PhD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, explore the concept of progression independent of relapse activity (PIRA) and the challenges of defining subtle accumulation of disability.
Hammer, a patient advocate living with acute flaccid myelitis, discussed the language around neurologic disability, and how the conversations should shift going forward. [WATCH TIME: 4 minutes]
Heterogeneity suggests that identifying different types of Parkinson disease could improve patient management, the understanding of underlying disease mechanisms, and the development of target-specific therapies.
Episode 37 of the AUPN Leadership Minute features David G. Standaert, MD, PhD, of the University of Alabama at Birmingham; and Erica A. Schuyler, MD, of the University of Connecticut. [WATCH TIME: 5 minutes]
The assistant professor of neurology at Mayo Clinic spoke about understanding the phenotypes and epidemiology of autoimmune encephalitis at the 2023 AAN Annual Meeting. [WATCH TIME: 4 minutes]
Dr Macaron shares her interpretation of the data and importance of individualizing treatment for patients with multiple sclerosis.
The head of the Laboratory of Clinical Pharmacology and Therapeutics at the University of Lisbon gave his perspective on the importance of the study population of this analysis.
The associate professor of neurology at Weill Cornell Medicine talked about a recent study that revealed that minimally invasive surgery significantly reduced the risk of mortality in patients with nontraumatic intracerebral hemorrhage. [WATCH TIME: 4 minutes]
The senior vice president of research at Gain Therapeutics talked about preclinical findings from a study assessing GT-02287, an agent in development for the treatment of GBA1 Parkinson disease, and future plans for clinical trials. [WATCH TIME: 7 minutes]
New training pathways are needed to close the gap between capable-physician supply and the growing demand for thrombectomy.
The panel shares final advice for the multiple sclerosis community.
The chief medical officer of Scholar Rock discussed the upcoming phase 3 trial for apitegromab in SMA and whether a successful trial would warrant FDA submission.
The pediatric neuromuscular neurologist at Arkansas Children's Hospital and associate professor of pediatrics at the University of Arkansas for Medical Sciences talked about findings from a phase 1/2 study on dosing 3 pediatric patients with Duchenne muscular dystrophy with REGENXBIO’s RGX-202. [WATCH TIME: 4 minutes]
The neurologist and senior research at the Amsterdam University Medical Centers’ Alzheimer Center discussed the reasons behind the use of quantitative EEG in assessing Cognition Therapeutics' Alzheimer agent CT1812. [WATCH TIME: 3 minutes]
As the treatment landscape for relapsing MS continues to strengthen, the neurologist at Allegheny Health Network discussed the reasons for continued pursuit of drug development. [WATCH TIME: 3 minutes]
The professor of psychiatry in neurology at the Gertrude H. Sergievsky Center at Columbia University Medical Center spoke about the possibility of using lithium for agitation in Alzheimer.